Affordable Innovation
| Name | Indication | Clinical Trial Phase | Study Title |
|---|---|---|---|
| HLX10+Chemotherapy |
Esophageal Squamous Cell Carcinoma
|
Phase III |
A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
|
| HLX10+Chemotherapy |
Non-Small-Cell Lung Cancer
|
Phase III |
A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
|
| HLX10+HLX04 |
Advanced Malignant Soild tumours
|
Phase I |
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination with Avastin Biosimilar (HLX04) in Patients with Advanced Solid Tumors |
| HLX10+HLX04 |
Hepatocellular Carcinoma
|
Phase II |
A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients With Disease Progression or Intolerant Toxicity After Standard Treatment
|
| HLX10 |
Advanced Soild Tumours
|
Phase I | Phase I Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients with Advanced Solid Tumors |
